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ABSTRACT 
Aims: Our study aimed to examine the prevalence of non-diabetic renal disease in selected 
patients with type 2 diabetes mellitus and to determine important risk factors for non-diabetic 
renal disease. 
Methods: We conducted retrospective analysis of clinical, laboratory and pathohistological 
data of type 2 diabetes mellitus patients in whom renal biopsies were performed from January 
2004 to February 2013 at Dubrava University Hospital Zagreb Croatia (n=80). 
Results: According to renal biopsy findings, isolated diabetic nephropathy was found in 
46.25%, non-diabetic renal disease superimposed on diabetic nephropathy in 17,5% and 
isolated non-diabetic renal disease in 36,25% of the patients. The most common non-diabetic 
renal diseases found were: membranous nephropathy, followed by IgA nephropathy and focal 
segmental glomerulosclerosis. In univariate analysis shorter duration of diabetes, 
independence of insulin therapy, lower levels of HbA1c and absence of diabetic retinopathy 
were found to be significant clinical predictors of non-diabetic renal disease. In multivariate 
analysis only independence of insulin therapy (OR 4.418, 95%CI=1.477-13.216) and absence 
of diabetic retinopathy (OR 5.579, 95%CI=1.788-17.404) were independent predictors of 
non-diabetic renal disease.  
Conclusions: This study confirmed usefulness of renal biopsy in patients with type 2 diabetes 
mellitus, due to the high prevalence of non-diabetic renal disease found. Since non-diabetic 
renal disease are potentially curable, we should consider renal biopsy in selected type 2 
diabetes mellitus patients with renal involvement, especially in those with absence of diabetic 
retinopathy and independence of insulin therapy. 
 
KEYWORDS: type 2 diabetes mellitus, diabetic nephropathy, diabetic retinopathy, renal 
biopsy, non-diabetic renal disease 
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INTRODUCTION 
The incidence and prevalence of type 2 diabetes mellitus (T2DM) are increasing and 
becoming one of the major health care problems in the world [1, 2]. Diabetic nephropathy 
(DN) is one of the major complications of diabetes mellitus and is reported as the leading 
cause of the end-stage renal disease (ESRD) worldwide [1, 3]. The diagnosis of DN is mostly 
clinical, based on duration of T2DM and the presence of retinopathy, neuropathy and other 
chronic complications, proteinuria and slowly progressing azothemia. This kind of diagnostic 
approach has been constantly challenged, due to the fact that other non-diabetic renal diseases 
(NDRD) have been found in T2DM patients. The prevalence of other biopsy-proven 
glomerular, tubulointerstitial and /or vascular diseases in T2DM in reported studies [4-27] 
varies considerably, ranging from 8% [4] to 93.5% [5]. This depends on the selection criteria, 
indications and availability of renal biopsy as well as on the population investigated. Despite 
the fact that NDRD in selected T2DM patients is not uncommon and renal biopsy is the only 
tool to absolutely identify DN or NDRD, the role of renal biopsy in T2DM patients with signs 
and symptoms of renal disease remains controversial. The findings of NDRD could have 
major therapeutic and prognostic implications, since the majority of glomerular and 
tubulointerstitial diseases are treatable, even remittable, which is quite different from DN. 
This is supported by the results of a recent study, which showed that the patients with NDRD 
have significantly better renal outcomes compared to patients with DN only [7]. The results of 
previous studies on discriminatory factors between DN and NDRD are not uniform, and there 
are differences in study populations and selection criteria [4-27]. The purpose of this study 
was to evaluate the indications of renal biopsy and to determine predictors of NDRD and DN 
in Croatian patients with T2DM referred to our center. In our center the majority of adult 
native renal biopsies in Croatia are performed, and our results were recently published [28].  
SUBJECTS, MATERIALS AND METHODS 
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Patients and methods 
The present study was conducted by reviewing the medical records of T2DM patients who 
underwent percutaneous renal biopsy in Dubrava University Hospital, Zagreb, Croatia from 
January 2004 to February 2013. All patients were diagnosed at the time of biopsy with T2DM 
as defined by the WHO, ADA and EDA [1, 29, 30]. Biopsy indications were uniform 
throughout the study period and were based on clinically strong suspicion of NDRD and 
included one or more of the following factors: heavy proteinuria or nephrotic syndrome, renal 
failure (acute, rapidly progressive or unexplained chronic), absence of diabetic retinopathy, 
findings of persistent glomerular hematuria, clinical or laboratory findings of systemic 
autoimmune disease or hematologic malignancy. The following clinical data were collected 
for each patient: age at the time of the biopsy, gender, duration of diabetes prior to biopsy, 
presence of hypertension (including systolic, diastolic and mean arterial pressure), presence of 
diabetic retinopathy, presence of glomerular hematuria, history of insulin therapy. Laboratory 
data collected at the time of the biopsy were as follows: urinalysis, serum creatinine, serum 
albumin and proteins, hemoglobin A1c (HbA1c), maximal 24-hour proteinuria, estimated 
glomerular filtration rate (EGFR, determined by the CKD-EPI formula). Ultrasound was used 
to determine kidney size and enlarged kidneys were defined as >12cm on the longitudinal axis 
bilaterally. Hypertension was defined as systolic blood pressure≥140mmHg or diastolic blood 
pressure≥90mmHg or antihypertensive medications being taken by the patient. Diabetic 
retinopathy was diagnosed by direct ophthalmoscopy performed by an ophthalmologist. 
Hematuria was defined as >3 red blood cells per high power microscope field in a centrifuged 
urine sample. Percutaneous renal biopsy using kidney biopsy gun (16G) was performed after 
obtaining a signed informed consent from each patient. Renal tissue obtained was sent for 
light, immunofluorescence and electron microscopic examination routinely. All biopsies were 
reviewed by two experienced and independent pathologists.  
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Only biopsies suitable for definitive diagnosis were included in the study. DN was diagnosed 
based on the presence of mesangial expansion and diffuse intercapillary glomerulosclerosis 
with or without Kimmelstiel-Wilson nodules, basement membrane thickening and exudative 
lesions, such as fibrin caps, capsular drop or hyaline thrombi [31]. Based on the biopsy 
findings, patients were divided into three basic groups: patients with isolated DN, patients 
with NDRD superimposed on DN (mixed lesions) and patients with isolated NDRD. Because 
we planned to investigate predictors for DN and for NDRD, we furthermore created two more 
classification groups, which distinguished patients on the basis of having DN (DN vs. non DN 
patients) and on the basis of having NDRD (NDRD vs. non NDRD patients). 
Statistical analysis 
Statistical analyses were performed using PASW Statistics (version 18.0, SPSS Inc. Chicago, 
IL, USA). Normally distributed data were expressed as mean±SD, skewed data as median 
with interquartile range and categorical data as frequency (%). Differences between groups 
were evaluated by Student t-test or ANOVA for normally distributed data, by Mann-Whitney 
U test or Kruskal-Wallis test for skewed data and by chi-square (χ
2
)-test for categorical data. 
Multiple logistic regression using forward stepwise method was performed to determine 
independent predictors for DN and for NDRD, including all covariates with a p-value of 
<0.05 in univariate analysis. Receiver operating characteristics (ROC) curves were 
constructed for significant variables of NDRD and DN by plotting sensitivity vs. 1-specificity 
and the areas under the ROC curves (AUC) were calculated for determining sensitivity and 
specificity of predictors. Significance was evaluated using a two-sided p value of <0.05. 
RESULTS 
80 patients with T2DM were included in this study. Mean age at biopsy was 59.5±9.8 
years, 70% of patients were male and median duration of diabetes was 10 years (ranging from 
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0-i.e. newly diagnosed disease to 39 years). The baseline clinical and laboratory data collected 
are shown in Table 1.  
The most common indication for renal biopsy was nephrotic syndrome (80%) and in 
75% of patients there was renal failure (acute, rapidly progressive or unexplained chronic). In 
43 patients NDRD was found on renal biopsy (29 patients had isolated NDRD and 14 patients 
had mixed lesions of NDRD and DN). In 51 patients DN was found (37 had isolated DN and 
14 patients had mixed lesions). NDRD found in our patients are shown in Table 2. The most 
common NDRD was membranous nephropathy in 9 patients (20.9%), followed by IgA 
nephropathy in 8 patients and focal segmental glomerulosclerosis (FSGS) in 8 patients also.  
 Univariate analysis of our basic classification groups (DN vs. mixed lesions vs. 
NDRD, Table 1.) demonstrated only significant difference regarding insulin therapy 
(p<0.000) and presence of diabetic retinopathy (p<0.000). 
Classification groups II (DN vs. non DN) comparison showed that patients having DN 
had significantly longer duration of diabetes (p<0.000), were more common on insulin 
therapy (p<0.000), had higher serum creatinine (p=0.012), lower EGFR (p=0.014) and had 
more common diabetic retinopathy (p<0.000) as compared with patients not having DN 
(Table 3.). 
Classification groups III (NDRD vs. non NDRD) univariate analysis revealed that 
patients with NDRD had shorter duration of diabetes (p=0.001), were less common dependent 
on insulin therapy (p<0.000), had lower serum HbA1c (p=0.006) and had less frequently 
diabetic retinopathy (p<0.000) as compared with patients not having NDRD (Table 3.). 
Multivariate logistic regression analysis was used to determine risk factors associated with 
DN and NDRD, and variables found statistically significant in univariate analysis were used. 
The results are summarized in Table 4. Significant risk factors for DN were duration of 
diabetes prior to biopsy (OR 1.183; 95%CI=1.070-1.308; p=0.001) and presence of diabetic 
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retinopathy (OR 24.531; 95%CI=2.862-210.278; p=0.004). Significant risk factors for NDRD 
were independence of insulin therapy (OR 4.418, 95%CI=1.477-13.216) and absence of 
diabetic retinopathy (OR 5.579, 95%CI=1.788-17.404). We evaluated sensitivity and 
specificity of those factors in prediction of DN and NDRD in ROC analysis, and results are 
summarized in Table 5. For DN duration of diabetes of more than 7 years (cut-off value 
determined by ROC analysis) showed highest AUC. When including duration of diabetes 
variable as categorical with cut-off value of 7 years, in the logistic regression model, OR for 
this variable in the prediction of DN was found to be 13.074 (95%CI=3.459-48.859). The 
AUC curves of the predictors for NDRD are shown in Figure 1. 
DISSCUSION 
 Diabetic nephropathy is the most common cause of ESRD worldwide [1, 3], while 
diagnosis of DN is frequently based on clinical criteria exclusively and patients with potential 
NDRD are often overlooked. Comparison of clinical diagnostic criteria and histologic 
findings of DN is usually not directly tested in recent studies [4-27], as well as in our study. 
This is probably due to the fact that the research priority is finding of predisposing factors of 
NDRD and not of DN. Only Biesenbach et al. found high sensitivity of clinical diagnosis in 
the prediction of DN [32]. The limitation of this study is that it is mostly post mortem study, 
and the advantage is that there aren’t any usual biases in selection criteria.  
In most cases NDRD are treatable and even curable diseases and therefore it is of great 
importance to diagnose and differentiate NDRD among T2DM patients with renal signs and 
symptoms. The prevalence of NDRD in published studies varies widely ranging from 8% to 
93.5% [4-27]. In our study it was 53.8%, which is most similar to findings of Mou S et al. [8]. 
Due to the fact that it is not ethical to perform kidney biopsy in all T2DM patients with renal 
involvement, we will never know the true prevalence of NDRD as well as that of DN in 
T2DM patients. In 1992, Waldherr et al. performed autopsy in 205 T2DM patients and found 
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NDRD in 0.4% and DN in 79% of the cases [33]. This post mortem study, as well as that of 
Biesenbach et al. [32], which included mostly ESRD patients, probably led to underestimation 
of NDRD in T2DM. The reason for this is that in ESRD, some cases of NDRD can’t be 
distinguished from DN, there is only advanced glomerular and tubulointerstitial scarring. This 
conclusion is supported by the findings of Biesenbach et al., which didn’t find any NDRD, 
but only DN and vascular nephropathy in their study [32]. 
The large variation in the reported prevalence of NDRD is mostly the results of the different 
criteria for renal biopsy and possibly due to geographical and ethnic differences also. In large 
majority of reported studies, as well as in ours, the main indication for renal biopsy was 
clinically thorough suspicion of NDRD. This usually includes any renal function abnormality 
and/or urine sediment abnormality (proteinuria, glomerular hematuria), which is not 
consistent with the typical course of T2DM [29, 31]. Majority of studies also report absence 
of diabetic retinopathy as the biopsy criteria [5-7, 9, 11-16]. Although relatively uniformly 
defined, there were minor differences among studies, regarding indications for biopsy, and 
also in some studies threshold criteria were not clearly defined. Common indications for renal 
biopsy in reported studies included acute or rapidly progressive renal failure [5, 6, 7, 9, 11-13, 
16], proteinuria [5-11, 13-17], glomerular hematuria [5-7, 9, 11-13, 16] and absence of 
diabetic retinopathy [5-7, 9, 11-13, 15, 16] as well as shorter duration of T2DM [5, 6, 8, 13]. 
This is in consistence with our indications for renal biopsy. Differences in selection criteria 
imply the necessity for standardization of renal biopsy criteria in T2DM. This refers in 
particular on renal function parameters (creatinine, EGFR) and proteinuria. In reported studies 
there is usually no clear threshold level of creatinine or EGFR bellow which biopsy is not 
performed, only in study of Zhou J et al. biopsy was contraindicated if serum creatinine was 
above 442µmol/l [10]. The serum creatinine level and/or EGFR should not be of importance 
when there is acute or rapidly progressive renal failure. Regarding proteinuria there are 
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usually not clearly defined threshold levels for renal biopsy, only a few researchers performed 
biopsy only when proteinuria was above 1g/24 hours [15, 17, 19]. Age, duration of diabetes 
and renal size on ultrasound are also factors that need to be uniformly defined as biopsy 
criteria. Some authors excluded patients older than 65-70 years [8, 15], and also if the 
duration of T2DM was longer than 10 years [8]. We believe that biopsy is probably of no 
importance when there is advanced chronic renal insufficiency with smaller, shrunken 
kidneys on ultrasound (at which EGFR level is still to be determined by future studies), 
because of expected findings of diffuse global glomerulosclerosis and tubular atrophia with 
interstitial fibrosis, without any reference to underlying disease.  
The incidence of NDRD in T2DM is mostly dependent on the threshold and criteria for 
performing renal biopsy and unifying will enable to extrapolate the findings of smaller local 
studies to larger populations, as well as to compare different populations and to perform meta-
analyses. Low threshold for biopsy probably explains high prevalence of NDRD in certain 
reports [34] and leads to overestimation of the NDRD prevalence in T2DM patients, and the 
opposite is the case in high thresholds for biopsy. 
 The most common NDRD reported are glomerulonephritides [7, 8, 10, 13, 14, 17, 21, 
22] which is consistent with our results. In some reports the most common NDRD was 
interstitial nephritis [6, 11]. Among glomerulonephritides, the most common found was IgA 
nephropathy [10, 13, 14, 17, 22], and in some reports it was FSGS [8, 21] or membranous 
nephropathy [7]. We found membranous nephropathy as the most common 
glomerulonephritis and as the most common NDRD also, followed by IgA nephropathy and 
FSGS. The complete and correct diagnosis of glomerular diseases depends on the use of 
immunofluorescence (IF) and electron microscopy (EM) in the analysis of renal biopsy. 
Immunofluorescence microscopy is crucial in the diagnosis of IgA nephropathy and also in 
differentiation between types of crescentic glomerulonephritides. EM is necessary for the 
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diagnosis of minimal change disease and also for the differentiation between primary and 
secondary FSGS. EM in some cases can also help diagnosing early DN (on the bases of 
thickened glomerular basement membranes). Some of the reported studies did not routinely 
use EM [6, 9, 11] and in our study EM was routinely used. We think this is one of the 
advantages of our study. In two studies vascular nephropathy is separated as a distinct entity, 
independently of DN and NDRD [32, 35]. In most studies, as well as in our study, vascular 
nephropathy was a part of NDRD spectrum (hypertensive nephrosclerosis). The problem with 
this diagnosis is that some authors believe that some pathohistological changes are 
concomitantly part of DN and also of hypertensive nephrosclerosis. 
 Due to the fact that there is still no general agreement on selection criteria for renal 
biopsy in T2DM patients, it is important to be able to identify clinical predictors of NDRD. 
Wide variation also exists in reported significant risk factors for NDRD [6, 7, 8, 10, 13, 14, 
17, 21, 22]. In our analysis of important predictors, we divided our patients into three 
classification groups. The reason for this is the fact that there is not always a clear distinction 
between DN and NDRD, i.e. that there are patients with mixed lesions (NDRD superimposed 
on DN) which is consistent with most reported studies [5-7, 11-13, 16, 17, 19, 20, 21, 23, 27]. 
Some studies didn’t find patients with mixed lesions [8, 10, 15, 24], while others reported no 
isolated NDRD [9, 14, 22]. It is difficult to determine the cause of lack of isolated NDRD or 
mixed lesions respectively in some studies. The potential causes include still uniform 
pathohistologic criteria for DN, lack of IF or EM use in some studies and also earlier 
mentioned different renal biopsy thresholds. We think that basic classification group I 
(isolated DN, mixed lesions, isolated NDRD; Table 1.) should serve only in descriptive 
purposes and not for the analysis of potential risk factors. The analysis in classification group 
III (NDRD vs. non-NDRD) is the most important for determination of risk factors because the 
presence of NDRD is a potential specific treatment target, whether there is isolated NDRD or 
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NDRD superimposed on DN (mixed lesions). We found in univariate analysis that shorter 
duration of T2DM, independence of insulin therapy, lower HbA1c and absence of diabetic 
retinopathy were significant risk factors for NDRD. In multivariate analysis independence of 
insulin therapy and absence of diabetic retinopathy were found significant independent 
predictors for NDRD. Absence of diabetic retinopathy is reported as significant predictor for 
NDRD in majority of studies in univariate analysis [7, 8, 10, 13, 21, 22], and in some of them 
also in multivariate analysis [7, 8, 10]. Minority of studies didn’t find absence of diabetic 
retinopathy as significant predictor for NDRD [6, 14]. This study therefore confirms the 
accepted view that the absence of diabetic retinopathy in T2DM patients with renal 
involvement should raise the possibility of NDRD, hence the renal biopsy. In our study, 
sensitivity and specificity of absence of diabetic retinopathy in prediction of NDRD was 
found 73.47% and 77.42% respectively. In comparison, Mou S et al. found sensitivity and 
specificity of 72.7% and 91.7% [8], and Wong TY et al. of 81.8% and 70.8% respectively 
[13]. Independence of insulin therapy was investigated in a few studies and was found as a 
significant predictor of NDRD only in the study of Wong TY et al. [13]. For the insulin 
therapy independence in prediction of NDRD, we didn’t find reported sensitivity or 
specificity in published studies for comparison. 
 In our study, other investigated clinical and laboratory variables were not found 
statistically significant predictors of NDRD in multivariate analysis. In published studies, 
shorter duration of diabetes was found significant predictor of NDRD in multivariate analysis 
in a few studies [7, 10], while in others, like in ours, it wasn’t found significant [6, 8, 13, 14, 
17, 21, 22]. We found longer duration of diabetes as a significant predictor of DN in 
multivariate analysis (for duration of >7 years, OR was 13,074) and for NDRD only in 
univariate analysis, which is similar to Chong YB et al. [6]. For clinicians, this is probably not 
decisive, because the presence of DN does not exclude NDRD. 
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 Age and gender were not significant predictors of NDRD in our study, which is 
consistent with the majority of findings [6, 8, 10, 13, 14, 17, 21, 22]. Only Chang TI et al. 
found increased age as a significant risk factor for NDRD, but only in univariate analysis [7]. 
Hypertension is often concomitant finding in patients with T2DM, but its predictive 
value of NDRD found, varies considerably. Hypertension was found as a significant predictor 
of NDRD in studies of Zhou J et al. [10] and Wong TY et al. [13], while other studies didn’t 
confirm this [6-8, 14, 17, 21, 22]. 
 Baseline morphometric variables (weight, height, body mass index) are not reported to 
be significant in prediction of NDRD in published studies [6-8, 10, 13, 14, 17, 21, 22], as well 
as in our study.  
 Variation exists in analysis of proteinuria as a predictor for NDRD. This is mostly due 
to different inclusion criteria for renal biopsy regarding proteinuria in T2DM patients. 
Majority of studies didn’t found proteinuria significant in prediction of NDRD [6-8, 10, 13, 
14, 21], similar to our results. Mak SK et al. found lower proteinuria as a significant predictor 
of NDRD [17], which is opposite to findings of Bi H et al., who found higher proteinuria as 
significant predictor of NDRD [22]. 
 Renal excretion function (measured by serum creatinine levels and/or estimated 
glomerular filtration rate in reported studies) was not found significant predictor of NDRD in 
our study as well as in majority of studies [8, 10, 14, 17, 21, 22]. In a few studies significantly 
linking renal function with NDRD, findings, like with proteinuria, were opposite. Chang TI et 
al. [7] and Mou S et al. [8] found lower serum creatinine levels as significant predictor of 
NDRD, while Chong YB et al. [6] found this for higher serum creatinine. As well as in the 
case of proteinuria, the opposite reported significance of serum creatinine in prediction of 
NDRD is probably reflected by the indications for renal biopsy. 
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 Hematuria is variably associated with NDRD. Some authors found that hematuria is 
infrequent in DN, while majority of glomerular diseases present with hematuria, and therefore 
hematuria becomes important differential indicator of NDRD vs. non-NDRD. This is 
supported by the results of some studies [6, 10, 17, 22]. Our results, don’t support these 
findings, and some other authors didn’t find hematuria significant as well [7, 8, 13, 14, 21]. 
 Serum protein and albumin levels were not found significant predictors of NDRD in 
majority of studies [6-8, 10, 17, 21, 22], and in our study as well. Only Suzuki D et al. found 
lower serum protein levels as a significant predictor of NDRD [14]. 
 We found lower serum HbA1c levels significantly associated with NDRD, but only in 
univariate analysis. Similar to this finding, most studies didn’t find its significance in 
prediction of NDRD, only Zhou J et al. found it significant in multivariate analysis [10]. 
 Other reported significant predictors of NDRD in T2DM patients include higher serum 
hemoglobin levels [7], higher cardiac ejection fraction, lower intima-media thickness and 
smaller carotid artery plaques [8]. 
 Our study has several obvious limitations. It is a retrospective study and therefore 
ascertainment error, recall, informative censoring and lead-time biases cannot be avoided. 
Since renal biopsy in patients included in our study was performed with a strong suspicion of 
NDRD, biases in selecting patients is another limitation of our study. We think that the 
advantages of our study are routine use of immunofluorescence and electron microscopy in 
renal biopsy analysis, no limitations in inclusion criteria regarding age and serum creatinine 
and also multivariate analysis. 
 In conclusion, high prevalence of NDRD in our study supports the decision for biopsy, 
and findings of NDRD implicated specific therapeutic approach. We think that findings of our 
study, in conjunction with other studies, imply that signs of renal disease in all T2DM patients 
cannot be confidently presumed to be due to DN, and that careful individual approach to each 
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patient regarding renal biopsy, is required. Renal biopsy should always be considered in 
selected group of T2DM patients with renal involvement. Since considerable variability in 
investigated and reported predictors for NDRD exists, further studies are needed to determine 
certain, clear, unbiased renal biopsy criteria. Until then, absence of diabetic retinopathy, 
nephrotic range proteinuria, acute or rapidly progressive renal failure, glomerular hematuria, 
independence of insulin therapy and shorter duration of diabetes are proposed as risk factors 
of NDRD in T2DM. 
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FIGURES 
Figure 1. Receiver operating characteristic curves in the analysis of predictors of non-diabetic 
renal disease. A for independence of insulin therapy, B for absence of diabetic retinopathy 
and C for combination of these two variables. 
 
 
 
 
20 
 
TABLES 
 
Table 1. Clinical and biochemical characteristics of the study patients in total and in 
classification groups I (isolated DN vs. mixed lesions vs. isolated NDRD) 
 
ALL 
(n=80) 
CLASSIFICATION GROUPS I 
DN (n=37) MIX (n=14) NDRD (n=29) 
Age (years) 59.5±9.8 58.9±8.8 61.9±11.4 59.1±10.4 
Gender (Male) 56 (70%) 24 (64.9%) 12 (85.7%) 20 (69%) 
Diabetes duration 
(years) 
10 (1.65-16.0) 15 (9-19) 14.5 (8-20) 1.8 (0.5-6.0) 
Insulin therapy 38 (47.5%) 27 (73%) 7 (50%) 4 (13.8%)
* 
Weight (kg) 89.5 (78.0-100.0) 90 (79-101) 90.25 (75-106) 89 (78-99) 
Height (cm) 170.7±8.5 171.8±8.7 170.1±9.5 169.6±8.0 
Body mass index 
(kg/m
2
) 
30.53 (27.52-
33.44) 
29.7 (26.12-
33.63) 
32.87 (28.41-36.68) 30.47 (28.13-32.77) 
Hypertension 59 (73.8%) 27 (73%) 12 (85.7%) 20 (69%) 
Systolic blood 
pressure (mmHg) 
150 (130-162.5) 160 (130-170) 155 (150-170) 140 (130-160) 
Diastolic blood 
pressure (mmHg) 
90 (80-97.5) 90 (80-95) 92.5 (70-100) 80 (80-90) 
Mean arterial 
pressure (mmHg) 
106.7 (96.7-120) 113.3 (98.3-120) 116.7 (103.3-120) 103.3 (93.3-113.3) 
Serum creatinine 
(µmol/l) 
154 (119.5-227.5) 160 (136-230) 211 (139-276) 134 (105-176) 
Estimated GFR 
(ml/minute) 
37.95 (25.68-
50.5) 
37.99 (24.75-
43.9) 
27.07 (19.03-45.03) 46.83 (32.19-63.67) 
24-hour proteinuria 
(g) 
5.64 (3.35-9.75) 4.84 (3.5-8.59) 6.65 (4-14) 4.5 (2.75-11.6) 
Serum albumins 
(g/l) 
33 (28-37.5) 33 (31-38) 34.5 (21-37) 33 (26.9-37) 
Hemoglobin A1c 
(%) 
6.95 (6.4-7.9) 7.5 (6.6-8.4) 6.85 (5.2-7.2) 6.8 (6.3-7.3) 
Hemoglobin A1c 
(mmol/mol) 
52 (46-63) 58 (49-68) 51 (33-55) 51 (45-56) 
ULS kidney 
enlargement 
21 (26.6%) 12 (32.4%) 5 (35.7%) 4 (14.3%) 
Nephrotic 
syndrome 
64 (80%) 29 (78.4%) 12 (85.7%) 23 (79.3%) 
Renal failure 60 (75%) 30 (81.1%) 12 (85.7%) 18 (62.1%) 
Hematuria 45 (56.3%) 23 (62.2%) 6 (42.9%) 16 (55.2%) 
Diabetic 
retinopathy 
31 (38.8%) 24 (64.9%) 6 (42.9%) 1 (3.4%)
* 
*
 p <0.05 (χ
2
-test); GFR=glomerular filtration rate; ULS=ultrasound; DN=diabetic nephropathy; NDRD=non-
diabetic renal disease; MIX=NDRD superimposed on DN. 
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Table 2. Non-diabetic renal disease found in our study patients 
Non-diabetic biopsy-proven renal disease All (n=43) 
NDRD + DN 
(n=14) 
NDRD only 
(n=29) 
AL amyloidosis 1 (2.3%) 0 1 (3.4%) 
Pauci-immune glomerulonephritis 2 (4.7%) 0 2 (6.9%) 
Fibrilary glomerulonephritis 1 (2.3%) 0 1 (3.4%) 
Focal segmental glomerulosclerosis 8 (18.6%) 3 (21.4%) 5 (17.2%) 
IgA nephropathy 8 (18.6%) 3 (21.4%) 5 (17.2%) 
Lupus nephritis 1 (2.3%) 0 1 (3.4%) 
Minimal change disease 3 (7.0%) 1 (7.1%) 2 (6.9%) 
Membranous nephropathy 9 (20.9%) 2 (14.3%) 7 (24.1%) 
Membranoproliferative glomerulonephritis 1 (2.3%) 0 1 (3.4%) 
Myeloma kidney 1 (2.3%) 0 1 (3.4%) 
Hypertensive nephrosclerosis 5 (11.6%) 4 (28.6%) 1 (3.4%) 
Postinfectious glomerulonephritis 1 (2.3%) 0 1 (3.4%) 
Tubulointerstitial nephritis 2 (4.6%) 1 (7.1%) 1 (3.4%) 
DN=diabetic nephropathy; NDRD=non-diabetic renal disease. 
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Table 3. Clinical and biochemical characteristics of the study patients in the classification 
groups II (DN vs. non-DN) and in the classification groups III (NDRD vs. non-NDRD) 
 
CLASSIFICATION GROUPS II CLASSIFICATION GROUPS III 
DN (n=51) no DN (n=29) NDRD (n=43) no NDRD (n=37) 
Age (years) 59.8±9.6 59.1±10.4 60±10.7 58.9±8.8 
Gender (Male) 36 (70.6%) 20 (69%) 32 (74.4%) 24 (64.9%) 
Diabetes duration 
(years) 
15 (8-19) 1.8 (0.5-6.0)
* 
3 (0.5-12) 15 (9-19)
* 
Insulin therapy 34 (66.7%) 4 (13.8%)
* 
11 (25.6%) 27 (73%)
* 
Weight (kg) 90 (78-102) 89 (78-99) 89 (78-99.5) 90 (79-101) 
Height (cm) 171.4±8.8 169.6±8.0 169.8±8.4 171.8±8.7 
Body mass index 
(kg/m
2
) 
30.59 (26.12-
34.2) 
30.47 (28.13-
32.77) 
30.74 (28.13-33.25) 29.7 (26.12-33.63) 
Hypertension 39 (76.5%) 20 (69%) 32 (74.4%) 27 (73%) 
Systolic blood 
pressure (mmHg) 
160 (130-170) 140 (130-160) 150 (130-160) 160 (130-170) 
Diastolic blood 
pressure (mmHg) 
90 (80-100) 80 (80-90) 90 (75-100) 90 (80-95) 
Mean arterial 
pressure (mmHg) 
113.3 (98.3-120) 
103.3 (93.3-
113.3) 
106.7 (93.3-116.7) 113.3 (98.3-120) 
Serum creatinine 
(µmol/l) 
170 (136-249) 134 (105-176)
* 
141 (109-225) 160 (136-230) 
Estimated GFR 
(ml/minute) 
33.57 (21.1-
44.35) 
46.83 (32.19-
63.67)
* 37.91 (26.32-56.85) 37.99 (24.75-43.9) 
24-hour 
proteinuria (g) 
5.8 (3.6-8.7) 4.5 (2.75-11.6) 5.67 (2.76-12) 4.84 (3.5-8.59) 
Serum albumins 
(g/l) 
34 (29-38) 33 (26.9-37) 33 (26-37) 33 (31-38) 
Hemoglobin A1c 
(%) 
7.1 (6.5-8.4) 6.8 (6.3-7.3) 6.8 (6.1-7.3) 7.5 (6.6-8.4)
* 
Hemoglobin A1c 
(mmol/mol) 
54 (48-68) 51 (45-56) 51 (43-56) 58 (49-68)
* 
ULS kidney 
enlargement 
17 (33.3%) 4 (14.3%) 9 (21.4%) 12 (32.4%) 
Nephrotic 
syndrome 
41 (80.4%) 23 (79.3%) 35 (81.4%) 29 (78.4%) 
Renal failure 42 (82.4%) 18 (62.1%) 30 (69.8%) 30 (81.1%) 
Hematuria 29 (56.9% 16 (55.2%) 22 (51.2%) 23 (62.2%) 
Diabetic 
retinopathy 
30 (58.8%) 1 (3.4%)
* 
7 (16.3%) 24 (64.9%)
* 
*
 p<0.05 (Mann-Whitney test for continuous and  χ
2
-test for categorical variables); GFR=glomerular filtration 
rate; ULS=ultrasound; DN=diabetic nephropathy; NDRD=non-diabetic renal disease. 
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Table 4. Multivariate logistic regression analysis of diabetic nephropathy and of non-diabetic renal 
disease 
Indicator 
β-
estimate 
Standard 
error 
p-value 
Odds 
ratio 
95% confidence interval 
For diabetic nephropathy 
Duration of diabetes  
(years) 
0.168 0.051 0.001 1.183 1.070-1.308 
Diabetic retinopathy  
(yes vs. no) 
3.200 1.096 0.004 24.531 2.862-210.278 
For non-diabetic renal disease 
Insulin therapy 
(no vs. yes) 
1.486 0.559 0.008 4.418 1.477-13.216 
Diabetic retinopathy  
(no vs. yes) 
1.719 0.580 0.003 5.579 1.788-17.404 
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Table 5. Sensitivity, specificity, positive and negative predictive values of significant variables in the 
prediction of diabetic nephropathy and of non-diabetic renal disease 
Variable AUC 
Sensitivity 
(%) 
Specificity 
(%) 
PPV (%) NPV (%) p-value 
Prediction of diabetic nephropathy 
Duration of diabetes  
(>7 years) 
0.828 78.43 82.76 88.9 68.6 <0.0001 
Diabetic retinopathy  
(yes vs. no) 
0.777 58.82 96.55 96.8 57.1 <0.0001 
Prediction of non-diabetic renal disease 
Insulin therapy 
(no vs. yes) 
0.736 76.19 71.05 74.4 73.0 <0.0001 
Diabetic retinopathy  
(no vs. yes) 
0.754 73.47 77.42 83.7 64.9 <0.0001 
Insulin therapy+ 
diabetic retinopathy 
(no vs. yes) 
0.759 82.66 68.89 67.4 83.8 <0.0001 
AUC= area under curve; PPV=positive predictive value; NPV=negative predictive value. 
 
